Resumo

GARCIA-LEZAMA, Melissa; CARRILLO-RUIZ, José Damián; MORENO-JIMENEZ, Sergio  e  ROLDAN-VALADEZ, Ernesto. WHO CNS5 2021 includes specific mutations in gliomas that can be identified with MRI quantitative biomarkers. Gac. Méd. Méx [online]. 2023, vol.159, n.2, pp.164-171.  Epub 24-Abr-2023. ISSN 2696-1288.  https://doi.org/10.24875/gmm.22000313.

In 2021, the latest version of the World Health Organization classification of central nervous system tumors (WHO CNS5) was published, which is considered an international standard. The first editions of this classification were based on histological characteristics and, subsequently, aspects related to new knowledge were incorporated. In the 2016 revision, molecular characteristics were implemented for the classification and staging of gliomas, such as the presence of mutations in IDH1 or IDH2. Currently, advanced magnetic resonance imaging (MRI) techniques allow assessing for the presence of 2-HG (increased oncometabolite that precedes IDH mutations), whereby IDH mutations can be indirectly identified, without invasive procedures being required. Advanced MRI is a growing field, highly useful for diagnosis and management of different pathologies. This document addresses the implications of WHO CNS5 classification in the evaluation of gliomas, as well as historical aspects, the bases of conventional MRI, and advanced MRI sequences useful in current classification.

Palavras-chave : Biomarkers; Glioblastoma; Gliomas; Magnetic resonance imaging.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )